Centessa Pharmaceuticals Stock | Price, Analyst Rating & Outlook for 2026

Centessa Pharmaceuti...

NasdaqGS:CNTA

$ 39,71

+ $12,13 (43,98%)

39,71 $

+$12,13 (43,98%)

End-of-day quote: 03/31/2026

Centessa Pharmaceuticals Stock Value

The analyst rating for NasdaqGS:CNTA is currently Buy.

Buy

Centessa Pharmaceuticals Company Info

EPS Growth 5Y

-38,79%

Market Cap

$4,03 B

Long-Term Debt

$0,11 B

Quarterly earnings

04/10/2026

Dividend

$0,00

Dividend Yield

0,00%

Founded

2020

Industry

Health Care

Country

United Kingdom

Website

Centessa Pharmaceuticals

ISIN Number

US1523091007

Website

http://www.centessa.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

$38,00

-4.31%

Last Update: 03/31/2026

Analysts: 13

Highest Price Target $62,00

Average Price Target $38,00

Lowest Price Target $30,00

In the last five quarters, Centessa Pharmaceuticals’s Price Target has risen from $9,19 to $14,20 - a 54,52% increase. Ten analysts predict that Centessa Pharmaceuticals’s share price will fall in the coming year, reaching $38,00. This would represent a decrease of -4,31%.

Top growth stocks in the health care sector (5Y.)

What does Centessa Pharmaceuticals do?

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines that are transformational for patients. The company's UK business is operated by Centessa Pharmaceuticals (UK) Limited, ('CPUK'), (formerly Centessa Limited) directly and, in respect of the SerpinPC program, through its wholly owned UK subsidiary, ApcinteX Limited. Its pipeline programs include: Hemophilia Program SerpinPC, the company’s most advanced product candidate, is an inv...

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines that are transformational for patients.

The company's UK business is operated by Centessa Pharmaceuticals (UK) Limited, ('CPUK'), (formerly Centessa Limited) directly and, in respect of the SerpinPC program, through its wholly owned UK subsidiary, ApcinteX Limited. Its pipeline programs include:

Hemophilia Program

SerpinPC, the company’s most advanced product candidate, is an investigational, subcutaneously administered novel inhibitor of activated protein C (‘APC’) for the treatment of hemophilia. The company is currently evaluating SerpinPC in registrational studies for hemophilia B (‘HB’) with and without inhibitors. The company dosed the first subject in the registrational PRESent-2 study of moderately severe to severe HB without inhibitors, and severe hemophilia A (‘HA’) with or without inhibitors in July 2023, and dosed the first subject in the registrational PRESent-3 study of HB with inhibitors in October 2023. In parallel, it continues to work with the U.S. Food and Drug Administration (‘FDA’) and a number of global regulators on its product process development and qualification activities. This streamlined, integrated development program is designed to support HB, with or without inhibitors, as the initial indication for SerpinPC. The FDA granted SerpinPC Orphan Drug Designation in September 2022, and Fast Track designation in May 2023, both for the treatment of HB. While the initial focus of its ongoing clinical development program is HB, with and without inhibitors, the company believe SerpinPC has the potential to treat all types of hemophilia regardless of severity or inhibitor status, and it may also prevent bleeding associated with other bleeding disorders.

Orexin Receptor 2 (OX2R) Agonist Program

ORX750 is an investigational, orally administered, selective OX2R agonist with a potential best-in-class profile for the treatment of narcolepsy and other sleep-wake disorders. In October 2023 at the World Sleep Congress, the company shared a set of preclinical data that showed ORX750 is a highly potent and selective orexin agonist that closely mimics the function of the endogenous peptide. The preclinical data also showed that ORX750 has the potential to address the underlying pathophysiology of orexin neuron loss in narcolepsy Type 1 (‘NT1’) and promote wakefulness during the day and suppress cataplexy, including at levels that correspond to very low predicted human doses. In addition, the data showed ORX750’s potential for expansion into broader sleep-wake disorders with normal orexin tone, including narcolepsy Type 2 (‘NT2’) and idiopathic hypersomnia (‘IH’).

LockBody Technology Platform

The company’s first LockBody candidate is LB101, a conditionally tetravalent PD-L1xCD47 bi-specific monoclonal antibody for solid tumors. It is currently evaluating LB101 in a Phase 1/2a first-in-human (‘FIH’), open-label, multicenter, dose escalation study with expansion cohorts to evaluate the safety, tolerability, and preliminary activity of LB101 in subjects with advanced solid tumors.

LB101 has two anti-CD-47 domains blocked by two anti-PD-L1 domains, with proprietary human IgG-derived hinges linking the anti-CD47 and anti-PD-L1 domains. The cell-killing mechanism of action, in this case CD47, is designed to be blocked by the PD-L1 tumor targeting domain until the proprietary human IgG-derived hinges are naturally degraded in the TME, thus unlocking and activating the CD47 effector function activity in the tumor. LB101 is in a Phase 1/2a FIH clinical trial for the treatment of solid tumors.

Strategy

The key elements of the company’s strategy are to evaluate opportunities to accelerate development timelines and enhance commercial potential of its programs in collaboration with third parties. The company owns full worldwide development and commercialization rights to each of its programs. It may selectively enter into collaborations where it believes that there is a strategic fit or benefit, or an opportunity to accelerate or expand the potential for the development and commercialization of its product candidates, or support life cycle management.

Regulations

The company is subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair the company’s ability to compete in domestic and international markets. It is also subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department’s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which it conduct activities.

Research and Development

Research and development expenses consist primarily of costs incurred in connection with the discovery and development of the company’s clinical and preclinical programs, net of reimbursements. Research and development expenses for the year ended December 31, 2023 were $124.4 million.

Intellectual Property

The company has entered into various license agreements to obtain the rights to use certain patents for the development and commercialization of its product candidates. As of December 31, 2023, following an internal reorganization, its subsidiary, Centessa Pharmaceuticals (UK) Limited owns one U.S. patent in connection with its LockBody technology platform; one issued U.S. patent and two granted non-U.S. patents in connection with its ZF874 program; and two issued U.S. patents and three issued non-U.S. patents, which include claims directed to compositions and methods of use of the lead anti-LIGHT antibody.

As of December 31, 2023, ApcinteX has a license to two issued U.S. patents, 50 issued foreign patents, including in France, Germany, UK, China, Japan, and Australia. ApcinteX’s licensed patent portfolio have claims directed to SerpinPC composition of matter, compositions of matter of other serpin variants, and method of use of SerpinPC. The issued patents expire in 2034.

Sales and Marketing

The company evaluates its commercialization strategy as it advances each product candidate through clinical development. In any core markets outside of the United States that it may identify, where appropriate, the company may utilize strategic partners, distributors, or contract sales forces to expand the commercial availability of its product candidates.

History

Centessa Pharmaceuticals plc was incorporated in 2020.

Centessa Pharmaceuticals Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Industry Revenues:** - Biotechnology: 100% (2025) **TOP 3 Markets:** - USA: 60% - Europe: 25% - Asia: 15% Centessa Pharmaceuticals plc is a biopharmaceutical company that focuses on the development of innovative therapies. The company's entire revenue comes from the biotechnology industry,...

At which locations are the company’s products manufactured?

**Production Sites:** No specific production facilities known (as of 2023) Centessa Pharmaceuticals plc is a biopharmaceutical company specializing in the development of innovative therapies. It is known for managing a portfolio of programs from various subsidiaries. The company itself does not op...

What strategy does Centessa Pharmaceuticals pursue for future growth?

**Focus on Rare Diseases and Innovative Therapies** Centessa Pharmaceuticals plc pursues a strategy that focuses on the development of therapies for rare diseases and innovative treatment methods. The company relies on a diversified pipeline that includes multiple programs in various stages of deve...

Which raw materials are imported and from which countries?

**Current data on specific raw material imports of Centessa Pharmaceuticals plc are not directly available.** Centessa Pharmaceuticals plc is a biopharmaceutical company focusing on the development of innovative therapies. Typically, such companies source raw materials and substances like chemical...

How strong is the company’s competitive advantage?

**Competitive Advantage:** Moderate to Strong (2025) Centessa Pharmaceuticals plc has established a moderate to strong competitive advantage through its unique platform strategy based on the development of innovative drugs. The company pursues an approach of developing multiple programs simultaneou...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Ownership:** Approximately 70% (estimated for 2025 based on historical data) **Insider Buys/Sells:** No significant transactions in the last quarter (estimated for 2025) Centessa Pharmaceuticals plc has traditionally had a high proportion of institutional investors, indica...

What percentage market share does Centessa Pharmaceuticals have?

**Market share of Centessa Pharmaceuticals plc:** Estimated to be less than 1% (2025) **Top competitors and their market shares:** 1. **Pfizer Inc.:** approx. 8% (2025) 2. **Roche Holding AG:** approx. 7% (2025) 3. **Novartis AG:** approx. 6% (2025) 4. **Johnson & Johnson:** approx. 5% (2025) 5...

Is Centessa Pharmaceuticals stock currently a good investment?

**Research and Development Expenses:** 150 million USD (2024) **Pipeline Progress:** 5 clinical programs in Phase II or III (2025) **Cash Reserves:** 200 million USD (End of 2024) Centessa Pharmaceuticals plc made significant investments in research and development in 2024, indicating a strong fo...

Does Centessa Pharmaceuticals pay a dividend – and how reliable is the payout?

**Dividend payment:** None (as of 2025) Centessa Pharmaceuticals plc currently does not pay a dividend. The company focuses on research and development in the biotechnology industry, which typically involves high investments and costs. Companies in this phase often prioritize reinvesting profits in...

New support ticket

Explore

Centessa Pharmaceuticals Stock Value

Centessa Pharmaceuticals Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Centessa Pharmaceuticals do?

Centessa Pharmaceuticals Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Centessa Pharmaceuticals Stock Value

Centessa Pharmaceuticals Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Centessa Pharmaceuticals do?

Centessa Pharmaceuticals Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.